Tags

Type your tag names separated by a space and hit enter

CADTH Canadian Drug Expert Committee Recommendation: Sucroferric Oxyhydroxide (Velphoro — Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease (ESRD) on dialysis

Publisher

Canadian Agency for Drugs and Technologies in Health
Ottawa (ON)

Language

eng

PubMed ID

31206285

Citation

CADTH Canadian Drug Expert Committee Recommendation: Sucroferric Oxyhydroxide (Velphoro — Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease (ESRD) on dialysis. Canadian Agency for Drugs and Technologies in Health, 2019, Ottawa (ON).
CADTH Canadian Drug Expert Committee Recommendation: Sucroferric Oxyhydroxide (Velphoro — Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease (ESRD) on dialysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
(2019). In CADTH Canadian Drug Expert Committee Recommendation: Sucroferric Oxyhydroxide (Velphoro — Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease (ESRD) on dialysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
CADTH Canadian Drug Expert Committee Recommendation: Sucroferric Oxyhydroxide (Velphoro — Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease (ESRD) on dialysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
* Article titles in AMA citation format should be in sentence-case
TY - BOOK T1 - CADTH Canadian Drug Expert Committee Recommendation: Sucroferric Oxyhydroxide (Velphoro — Vifor Fresenius Medical Care Renal Pharma Ltd.): Indication: For the control of serum phosphorus levels in adult patients with end-stage renal disease (ESRD) on dialysis Y1 - 2019/01/04/ PY - 2019/6/18/pubmed PY - 2019/6/18/medline PY - 2019/6/18/entrez PB - Canadian Agency for Drugs and Technologies in Health CY - Ottawa (ON) UR - https://www.unboundmedicine.com/medline/citation/31206285/CADTH_Canadian_Drug_Expert_Committee_Recommendation:_Sucroferric_Oxyhydroxide_(Velphoro_—_Vifor_Fresenius_Medical_Care_Renal_Pharma_Ltd.):_Indication:_For_the_control_of_serum_phosphorus_levels_in_adult_patients_with_end-stage_renal_disease_(ESRD)_on_dialysis L2 - https://www.ncbi.nlm.nih.gov/books/NBK542404 DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows